Division of Thoracic Surgery, Department of Surgery, Tokyo Medical University, Tokyo, Japan.
Eur J Cardiothorac Surg. 2012 Sep;42(3):414-9. doi: 10.1093/ejcts/ezs065. Epub 2012 Mar 6.
Although an association between prognosis and lobar location of lung cancer, particularly the left lower lobe (LLL), has been suggested, the certainty of such association remains controversial. The purpose of this study was to evaluate the impact of tumour lobar location on surgical outcomes as an independent prognostic factor for survival in our non-small cell lung cancer (NSCLC) patient series.
We retrospectively reviewed 978 NSCLC patients who underwent complete resection in our hospital between 2000 and 2007. We statistically analysed the association between clinicopathological factors and clinical outcomes.
Among the 978 patients reviewed, the NSCLC was located in the LLL in 143 (14.6%) patients, and lymph node involvement was identified in 210 patients (21.5%). The 5-year overall survival rates of patients whose NSCLC was located in the LLL and in other lobes (non-LLL) were 73.1 and 74.3%, respectively, and showed no significant association (P = 0.86). On the other hand, the 5-year survival rates of patients whose NSCLC occurred in the LLL (n = 33) and non-LLL (n = 177) and with lymph node metastasis were 32.7 and 57.7%, respectively, and showed a significant association (P = 0.01). Therefore, we performed a more detailed analysis on the 210 NSCLC patients with lymph node metastasis. On multivariate analysis, we found that LLL tumour (P = 0.02), tumour size >3 cm (P = 0.02) and N status (P < 0.001) were significant independent predictors for survival.
LLL tumours with lymph node metastasis are strongly associated with mortality in NSCLC patients. The location of the primary tumour may contribute in determining the optimal management strategy and accurate prediction of prognosis.
尽管已有研究提示肺癌的预后与肺叶部位,特别是左下叶(LLL)相关,但这种相关性的确切性仍存在争议。本研究旨在评估肿瘤肺叶部位是否为影响生存的独立预后因素,作为我们非小细胞肺癌(NSCLC)患者系列中的手术结果的预测因素。
我们回顾性分析了 2000 年至 2007 年间在我院接受完全切除术的 978 例 NSCLC 患者。我们对临床病理因素与临床结果之间的关系进行了统计学分析。
在 978 例患者中,143 例(14.6%)的 NSCLC 位于 LLL,210 例(21.5%)患者存在淋巴结受累。位于 LLL 和非 LLL(非 LLL)的 NSCLC 患者的 5 年总生存率分别为 73.1%和 74.3%,无显著差异(P=0.86)。另一方面,在发生 LLL(n=33)和非 LLL(n=177)且伴有淋巴结转移的 NSCLC 患者中,5 年生存率分别为 32.7%和 57.7%,存在显著差异(P=0.01)。因此,我们对 210 例有淋巴结转移的 NSCLC 患者进行了更详细的分析。多变量分析发现,LLL 肿瘤(P=0.02)、肿瘤直径>3cm(P=0.02)和 N 分期(P<0.001)是生存的独立预测因素。
伴淋巴结转移的 LLL 肿瘤与 NSCLC 患者的死亡率密切相关。原发肿瘤的位置可能有助于确定最佳的治疗策略和准确预测预后。